Featured Image
Why is it important?
To describe targeted therapies for thrombotic microangiopathy
Perspectives
Targeted therapies with caplacizumab and ravulizumab are expected to reduce the burden of exacerbation, refractory disease, recurrence, and possibly death for thrombotic microangiopathy.
Dr. Clement Chung
Houston Methodist
Read the Original
This page is a summary of: New Therapeutic Targets and Treatment Options for Thrombotic Microangiopathy: Caplacizumab and Ravulizumab, Annals of Pharmacotherapy, July 2020, SAGE Publications,
DOI: 10.1177/1060028020941852.
You can read the full text:
Contributors
The following have contributed to this page
